富馬地羅昔美
外觀
臨床資料 | |
---|---|
商品名 | Vumerity |
其他名稱 | ALKS-8700 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620002 |
核准狀況 | |
懷孕分級 | |
給藥途徑 | 口服給藥 |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
血漿蛋白結合率 | Monomethyl fumarate (MMF): 27–45% |
藥物代謝 | Esterases, citric acid cycle |
代謝產物 | MMF (active), hydroxyethyl succinimide (HES, inactive), CO2 (inactive) |
生物半衰期 | 1 hour |
排泄途徑 | MMF: 60% lung, 15.5% urine (?), 0.9% faeces HES: 58–63% urine |
識別資訊 | |
CAS號 | 1577222-14-0 |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C11H13NO6 |
摩爾質量 | 255.23 g·mol−1 |
3D模型(JSmol) | |
| |
|
富馬地羅昔美(英語:Diroximel fumarate,商品名:Vumerity)是一種含氮有機化合物,化學式為C11H13NO6,用於治療復髮型多發性硬化症(MS)[3][5][6]。
參考文獻
[編輯]- ^ 1.0 1.1 Vumerity APMDS. Therapeutic Goods Administration (TGA). 4 April 2022 [24 April 2022].
- ^ Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 21 December 2022 [2 January 2023].
- ^ 3.0 3.1 Vumerity- diroximel fumarate capsule. DailyMed. [1 February 2021]. (原始內容存檔於5 February 2021).
- ^ Vumerity EPAR. European Medicines Agency. 14 September 2021 [24 November 2021]. (原始內容存檔於25 November 2021).
- ^ Wang Y, Bhargava P. Diroximel fumarate to treat multiple sclerosis. Drugs of Today. July 2020, 56 (7): 431–437. PMID 32648853. S2CID 220471534. doi:10.1358/dot.2020.56.7.3151521.
- ^ Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, Rybalka E. Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?. Pharmaceuticals (Basel, Switzerland). October 2020, 13 (10): 306. PMC 7602023 . PMID 33066228. doi:10.3390/ph13100306 .